What is Ninlaro (ixazomib) for?
Ninlaro (Ixazomib) is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
How does Ninlaro (ixazomib) work?
Ninlaro (ixazomib) targets and reversibly inhibits the proteasome enzyme complex within the cell. Proteasome is part of the cellular machinery, and among its functions, it regulates cellular division and survival. By interfering with proteasome’s function, ixazomib can lead to apoptosis (cell death)2.
Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines1.
Is Ninlaro (ixazomib) approved?
Ixazomib was approved or the treatment of patients with multiple myeloma who have received at least one prior therapy1 by:
Food and Drug Administration (FDA) (USA) September 20, 2015
Therapeutic Goods Administration (TGA) (AUS) November 15, 2016
European Medicines Agency (EMA) (EUR) EMA November 24, 20165
How do I take Ninlaro (ixazomib)?
The standard dosage is:
4 mg taken orally on Days 1, 8, and 15 of a 28-day cycle
Dose should be taken at least one hour before or at least two hours after food
The dose may be reduced to 3 mg and to 2.3 mg in patients with moderately or severely reduced liver function and patients with severely reduced kidney function
Complete information about ixazomib dosage and administration can be found in the resources section.
Consult your treating doctor for personalised dosing.
